Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents.

Lin PJ, Concannon TW, Greenberg D, Cohen JT, Rossi G, Hille J, Auerbach HR, Fang CH, Nadler ES, Neumann PJ.

Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):513-22. doi: 10.1586/14737167.2013.814948.

PMID:
23977977
2.

Assessing preferences for prevention versus treatment using willingness to pay.

Corso PS, Hammitt JK, Graham JD, Dicker RC, Goldie SJ.

Med Decis Making. 2002 Sep-Oct;22(5 Suppl):S92-101.

PMID:
12369235
3.

Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.

Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, Prosser LA.

Pharmacoeconomics. 2009;27(12):1005-16. doi: 10.2165/11314000-000000000-00000.

PMID:
19908925
4.

Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents.

Neumann PJ, Cohen JT, Hammitt JK, Concannon TW, Auerbach HR, Fang C, Kent DM.

Health Econ. 2012 Mar;21(3):238-51. doi: 10.1002/hec.1704. Epub 2010 Dec 28.

PMID:
22271512
5.

Valuation of symptomatic hepatitis a in adults: estimates based on time trade-off and willingness-to-pay measurement.

Jacobs RJ, Moleski RJ, Meyerhoff AS.

Pharmacoeconomics. 2002;20(11):739-47.

PMID:
12201793
6.

Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices.

Wong YN, Hamilton O, Egleston B, Salador K, Murphy C, Meropol NJ.

Oncologist. 2010;15(6):566-76. doi: 10.1634/theoncologist.2009-0307. Epub 2010 May 23.

7.

Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective.

Fautrel B, Clarke AE, Guillemin F, Adam V, St-Pierre Y, Panaritis T, Fortin PR, Menard HA, Donaldson C, Penrod JR.

J Rheumatol. 2005 Mar;32(3):443-53.

PMID:
15742435
8.

Patient preferences for depression treatment programs and willingness to pay for treatment.

Morey E, Thacher JA, Craighead WE.

J Ment Health Policy Econ. 2007 Jun;10(2):73-85.

PMID:
17603148
9.

Analysis of willingness to pay for implantable cardioverter-defibrillator therapy.

Nowakowska D, Guertin JR, Liu A, Abrahamowicz M, Lelorier J, Lespérance F, Brophy JM, Rinfret S.

Am J Cardiol. 2011 Feb 1;107(3):423-7. doi: 10.1016/j.amjcard.2010.09.041.

PMID:
21257009
10.

The willingness to pay for in vitro fertilization: a pilot study using contingent valuation.

Neumann PJ, Johannesson M.

Med Care. 1994 Jul;32(7):686-99.

PMID:
8028404
11.
12.

Different ways to describe the benefits of risk-reducing treatments: a randomized trial.

Halvorsen PA, Selmer R, Kristiansen IS.

Ann Intern Med. 2007 Jun 19;146(12):848-56.

PMID:
17577004
13.

The impact of risk information on patients' willingness to pay for autologous blood donation.

Lee SJ, Liljas B, Neumann PJ, Weinstein MC, Johannesson M.

Med Care. 1998 Aug;36(8):1162-73.

PMID:
9708589
14.

Perception of the economic value of primary care services: a Willingness to Pay study.

Martín-Fernández J, Gómez-Gascón T, Oliva-Moreno J, del Cura-González MI, Domínguez-Bidagor J, Beamud-Lagos M, Sanz-Cuesta T.

Health Policy. 2010 Mar;94(3):266-72. doi: 10.1016/j.healthpol.2009.11.001. Epub 2009 Nov 28.

PMID:
19945763
15.

Willingness to pay for child survival: results of a national survey in Central African Republic.

Weaver M, Ndamobissi R, Kornfield R, Blewane C, Sathe A, Chapko M, Bendje N, Nguembi E, Senwara-Defiobona J.

Soc Sci Med. 1996 Sep;43(6):985-98.

PMID:
8888468
16.

Community and patient values for preventing herpes zoster.

Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, Prosser LA.

Pharmacoeconomics. 2008;26(3):235-49.

PMID:
18282017
17.

Willingness to pay for praziquantel treatment in a hyperendemic community of Ogun State, Nigeria.

Adeneye AK, Mafe MA, Appelt B, Idowu ET, Akande DO.

Res Social Adm Pharm. 2006 Mar;2(1):83-95.

PMID:
17138502
18.

Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions.

Greenberg D, Hammerman A, Vinker S, Shani A, Yermiahu Y, Neumann PJ.

Value Health. 2013 Jul-Aug;16(5):842-7. doi: 10.1016/j.jval.2013.04.010. Epub 2013 Jul 11.

20.

Willingness to pay for drug abuse treatment: results from a contingent valuation study in Taiwan.

Tang CH, Liu JT, Chang CW, Chang WY.

Health Policy. 2007 Jul;82(2):251-62. Epub 2006 Nov 3.

PMID:
17084480

Supplemental Content

Support Center